Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

The promise of in silico drug development to improve patient outcomes

Tanja Dowe
Meds
July 2, 2022
Share
Tweet
Share

In the last two years, pharmaceutical companies have become increasingly interested in the possibilities in silico technologies bring to the world’s multi-billion-dollar drug development market. Among the factors that have been reported as drivers of recent interest in what is also known as virtual clinical trials are the COVID-19-related restrictions that began impacting traditional human-based clinical trials in 2020.

In silico drug development utilizes real-world data (RWD), artificial intelligence (AI), computational biology, and mechanistic modeling to predict the efficacy and safety of drug treatments or to simulate control arms in clinical trials. By reducing the risk of failure or the size of control arms, in silico drug development is cost-effective and promises to create safer, more efficient drug development, reducing the time it takes to bring a drug to market. Although it represents only a small fraction of the annual global spend on drug development, the value of the in silico drug development market is expected to reach nearly $3 billion by the end of 2022.

Also, most importantly, by accelerating research and development (R&D) timelines, in silico drug development has the potential to bring better outcomes to patients faster.

With the goal of reducing R&D costs and time-to-market of novel therapies, some companies perform in silico simulation in different stages of drug development for pharma and biotech companies throughout the world. In silico simulation reduces R&D decision-related risks by predicting the clinical benefits of new drugs before a human trial is conducted and helps identify ineffective therapies at an early stage, or partly replaces and complements costly clinical study control arms, saving drug developers time and money.

U.S. regulators weigh in on reduced animal testing

Regulatory agencies also recognize the value of the virtual clinical trial model and regulators are expected to endorse an increasing range of therapies that begin their development journey in an in silico trial. In its report entitled 2021 Advancing Regulatory Science at FDA: Focus Areas of Regulatory Science, the U.S. Food and Drug Administration stated that the emergence of in silico trials has the potential to “replace, reduce, and refine reliance on animal testing.”

According to the report, “In some cases, in silico modelings such as using available information in computational science approaches to predict safety issues, can be used to supplement and may potentially replace risk analyses that are currently based on animal data.” By relying less on animal testing, pharma and biotech companies will have the advantage of utilizing more human-based data in the development of novel therapies.

Giving patients access to personalized medicine

In silico technologies also enable drug developers to perform, in theory, an unlimited number of tests using a wide range of variables that include age, sex, and the health status of each member of the virtual patient pool, compared to the more restrictive parameters of a traditional trial. By reducing the amount of trial and error involved in collecting data, drug developers can focus on therapies that prove to be more effective in treating a specific group of patients.

This increase of data related to the way a drug impacts specific patient populations will also help drive the development of personalized medicine. By performing in silico studies, drug makers will have the opportunity to develop better-targeted therapies for patients with critical diseases such as cancer, through the benefit of data that provides a deeper look at how each patient reacts to a treatment.

As the prevalence of in silico drug development increases in the years ahead, the pharmaceutical and biotech community is optimistic that more effective and affordable treatments will become available to the people who need them, and positive patient outcomes will rise dramatically.

Tanja Dowe is a health care executive. 

Image credit: Shutterstock.com

Prev

5 tips for treating high-weight patients

July 2, 2022 Kevin 0
…
Next

When the music stopped

July 2, 2022 Kevin 0
…

Tagged as: Medications

Post navigation

< Previous Post
5 tips for treating high-weight patients
Next Post >
When the music stopped

Related Posts

  • 3 medical student tips to improve patient communication

    Subha Mohan
  • How value-based pay can worsen patient outcomes

    Matthew Hahn, MD
  • Do quality metrics really improve patient care?

    Fred N. Pelzman, MD
  • Physicians and patients must work together to improve health care

    Michele Luckenbaugh
  • A universal patient medical record

    Michael R. McGuire
  • A patient waits. And waits.

    Michele Luckenbaugh

More in Meds

  • 13.1 million missing Americans since 1980. Where’s the outrage?

    Steve Burgess, MD
  • Ketamine for mental health conditions: What every primary care physician needs to know

    Carlene MacMillan, MD & L. Alison McInnes, MD
  • Learn to be a Narcan hero: a comic tutorial

    Emily Watters, MD
  • The preference for insurance coverage of opioids over non-pharmaceutical options explained

    Amy Baxter, MD
  • A comic reveals the terrifying truth about fentanyl

    Emily Watters, MD
  • The importance of physician education regarding psilocybin therapy

    Lynn Marie Morski, MD, JD
  • Most Popular

  • Past Week

    • I’m a doctor, and I almost died during childbirth

      Bayo Curry-Winchell, MD | Physician
    • Unveiling excessive medical billing and greed

      Amol Saxena, DPM, MPH | Policy
    • Misinformed claims and the offensiveness of discrediting COVID-19 vaccine development

      Angel Garcia Otano, MD | Conditions
    • Dying is a selfish business

      Nancie Wiseman Attwater | Conditions
    • Navigating medical decision-making: Embracing limits and growth

      Benjamin Wade Frush, MD | Physician
    • Empathy and compassion in palliative care [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Medical gaslighting: a growing challenge in today’s medical landscape

      Tami Burdick | Conditions
    • Balancing opioid medication in chronic pain

      L. Joseph Parker, MD | Conditions
    • I want to be a doctor who can provide care for women: What states must I rule out for my medical education?

      Nandini Erodula | Education
    • Navigating the broken medical system: challenges faced by foreign medical graduates

      Anonymous | Physician
    • Mourning the silent epidemic: the physician suicide crisis and suggestions for change

      Amna Shabbir, MD | Physician
    • The essence of medicine: genuine connections in practice

      Jennifer Tillman, MD | Physician
  • Recent Posts

    • Misinformed claims and the offensiveness of discrediting COVID-19 vaccine development

      Angel Garcia Otano, MD | Conditions
    • Bitcoin’s role in diversified portfolios [PODCAST]

      The Podcast by KevinMD | Podcast
    • 1 in 5 doctors will become disabled. Are you prepared?

      Amarish Dave, DO | Finance
    • The pros and cons of whole life insurance for high-income earners

      Shane Tenny, CFP | Finance
    • Family support is pivotal in the treatment of schizophrenia

      Frank Chen, MD | Conditions
    • Is emergency medicine your calling? [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • Reduced Mortality Seen in Cancer Survivors Who Meet Exercise Guidelines
  • CDC Advisors Endorse Maternal RSV Vax to Protect Newborns
  • Amoxicillin Alone for Acute Sinusitis Holds Up Against Broad-Spectrum Cousin
  • Despite Taboo, Med Students, Doctors Use Substances Too
  • White House Opens Gun Violence Prevention Office

Meeting Coverage

  • Loneliness Needs to Be Treated Like Any Other Health Condition, Researcher Suggests
  • Stopping Medical Misinformation Requires Early Detection
  • AI Has an Image Problem in Healthcare, Expert Says
  • Want Better Health Outcomes? Check Out What Other Countries Do
  • ERS Roundup: Cell Transplant Boosts Lung Function in COPD Patients
  • Most Popular

  • Past Week

    • I’m a doctor, and I almost died during childbirth

      Bayo Curry-Winchell, MD | Physician
    • Unveiling excessive medical billing and greed

      Amol Saxena, DPM, MPH | Policy
    • Misinformed claims and the offensiveness of discrediting COVID-19 vaccine development

      Angel Garcia Otano, MD | Conditions
    • Dying is a selfish business

      Nancie Wiseman Attwater | Conditions
    • Navigating medical decision-making: Embracing limits and growth

      Benjamin Wade Frush, MD | Physician
    • Empathy and compassion in palliative care [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Medical gaslighting: a growing challenge in today’s medical landscape

      Tami Burdick | Conditions
    • Balancing opioid medication in chronic pain

      L. Joseph Parker, MD | Conditions
    • I want to be a doctor who can provide care for women: What states must I rule out for my medical education?

      Nandini Erodula | Education
    • Navigating the broken medical system: challenges faced by foreign medical graduates

      Anonymous | Physician
    • Mourning the silent epidemic: the physician suicide crisis and suggestions for change

      Amna Shabbir, MD | Physician
    • The essence of medicine: genuine connections in practice

      Jennifer Tillman, MD | Physician
  • Recent Posts

    • Misinformed claims and the offensiveness of discrediting COVID-19 vaccine development

      Angel Garcia Otano, MD | Conditions
    • Bitcoin’s role in diversified portfolios [PODCAST]

      The Podcast by KevinMD | Podcast
    • 1 in 5 doctors will become disabled. Are you prepared?

      Amarish Dave, DO | Finance
    • The pros and cons of whole life insurance for high-income earners

      Shane Tenny, CFP | Finance
    • Family support is pivotal in the treatment of schizophrenia

      Frank Chen, MD | Conditions
    • Is emergency medicine your calling? [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...